Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above 200-Day Moving Average – Time to Sell?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $34.94 and traded as high as $43.50. Global X Genomics & Biotechnology ETF shares last traded at $43.38, with a volume of 4,967 shares traded.

Global X Genomics & Biotechnology ETF Stock Up 1.0%

The stock has a market capitalization of $52.92 million, a price-to-earnings ratio of -18.54 and a beta of 1.03. The company’s 50-day simple moving average is $38.82 and its 200 day simple moving average is $34.94.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Several hedge funds have recently bought and sold shares of the business. Oxinas Partners Wealth Management LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 12.1% in the second quarter. Oxinas Partners Wealth Management LLC now owns 16,212 shares of the company’s stock valued at $137,000 after purchasing an additional 1,751 shares during the last quarter. Atria Investments Inc grew its position in shares of Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after purchasing an additional 2,073 shares during the last quarter. HighTower Advisors LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock valued at $121,000 after purchasing an additional 2,184 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 18.5% in the first quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock valued at $125,000 after purchasing an additional 2,329 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 14.3% in the first quarter. Private Advisor Group LLC now owns 20,738 shares of the company’s stock valued at $165,000 after purchasing an additional 2,587 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.